225 related articles for article (PubMed ID: 16538492)
1. Instrumental clinical restaging, pathological evaluation, and tumor regression grading: how to assess the response to neoadjuvant chemoradiotherapy for rectal cancer.
Benzoni E; Terrosu G; Intersimone D; Milan E; Chiaulon G; Bresadola V; Sacco C; Sattin E; Bresadola F; Avellini C
Int J Colorectal Dis; 2007 Jan; 22(1):7-13. PubMed ID: 16538492
[TBL] [Abstract][Full Text] [Related]
2. [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy].
Li SJ; Wang L; Zhang XY; Li YH; Li ZW; Wu Q; Sun YS; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jul; 22(7):648-655. PubMed ID: 31302963
[No Abstract] [Full Text] [Related]
3. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
4. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
Madbouly KM; Hussein AM; Abdelzaher E
Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
[TBL] [Abstract][Full Text] [Related]
5. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
[TBL] [Abstract][Full Text] [Related]
6. Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET.
Capirci C; Rubello D; Chierichetti F; Crepaldi G; Carpi A; Nicolini A; Mandoliti G; Polico C
Biomed Pharmacother; 2004 Oct; 58(8):451-7. PubMed ID: 15464875
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
Wheeler JM; Dodds E; Warren BF; Cunningham C; George BD; Jones AC; Mortensen NJ
Dis Colon Rectum; 2004 Dec; 47(12):2025-31. PubMed ID: 15657650
[TBL] [Abstract][Full Text] [Related]
8. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy.
Huh JW; Kim HC; Kim SH; Park YA; Cho YB; Yun SH; Lee WY; Park HC; Choi DH; Park JO; Park YS; Chun HK
Surgery; 2019 Mar; 165(3):579-585. PubMed ID: 30314723
[TBL] [Abstract][Full Text] [Related]
10. The outcome and the frequency of pathological complete response after neoadjuvant radiotherapy in curative resections for advanced rectal cancer: a population-based study.
Wasmuth HH; Rekstad LC; Tranø G
Colorectal Dis; 2016 Jan; 18(1):67-72. PubMed ID: 26201935
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of clinical evaluation of response to neoadjuvant chemoradiation therapy for rectal cancer.
Benzoni E; Cerato F; Cojutti A; Milan E; Pontello D; Chiaulon G; Sacco C; Bresadola V; Terrosu G
Tumori; 2005; 91(5):401-5. PubMed ID: 16459636
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumour regression grading and depth of neoplastic infiltration within the perirectal fat after combined neoadjuvant chemo-radiotherapy and surgery for rectal cancer.
Benzoni E; Intersimone D; Terrosu G; Bresadola V; Cojutti A; Cerato F; Avellini C
J Clin Pathol; 2006 May; 59(5):505-12. PubMed ID: 16522747
[TBL] [Abstract][Full Text] [Related]
13. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
[TBL] [Abstract][Full Text] [Related]
14. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
15. [Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?].
Liersch T; Langer C; Jakob C; Müller D; Ghadimi BM; Siemer A; Markus PM; Füzesi L; Becker H
Chirurg; 2003 Mar; 74(3):224-34. PubMed ID: 12647079
[TBL] [Abstract][Full Text] [Related]
16. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Edden Y; Wexner SD; Berho M
Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
[TBL] [Abstract][Full Text] [Related]
17. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].
Mátrai Z; Lövey J; Hitre E; Orosz Z; Gödény M; Péley G; Sulyok Z; Rényi Vámos F; Farkas E; Köves I
Orv Hetil; 2006 Oct; 147(42):2011-20. PubMed ID: 17165600
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings?
Pastor C; Subtil JC; Sola J; Baixauli J; Beorlegui C; Arbea L; Aristu J; Hernandez-Lizoain JL
Dis Colon Rectum; 2011 Sep; 54(9):1141-6. PubMed ID: 21825895
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
Bertolini F; Chiara S; Bengala C; Antognoni P; Dealis C; Zironi S; Malavasi N; Scolaro T; Depenni R; Jovic G; Sonaglio C; Rossi A; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):466-72. PubMed ID: 19004567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
